Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:53:42 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ICPT - INTERCEPT PHARMACEUTICALS INC - http://www.icpotash.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ICPT - QHALTED19.00    21.86  8.8216Nov 07Feb 2915 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-02-29 08:30U:ICPTNews ReleaseIntercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva(TM) (obeticholic acid) for the Treatment of PBC
2023-11-13 08:00U:ICPTNews ReleaseIntercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting ‚ ® 2023
2023-11-10 08:00U:ICPTNews ReleaseIntercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting ‚ ® 2023
2023-11-08 09:14U:ICPTNews ReleaseAlfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
2023-09-26 08:00U:ICPTNews ReleaseAlfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
2023-09-05 08:30U:ICPTNews ReleaseIntercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
2023-08-02 07:00U:ICPTNews ReleaseIntercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
2023-07-26 08:00U:ICPTNews ReleaseIntercept to Announce Second Quarter 2023 Financial Results on August 2, 2023
2023-06-23 06:30U:ICPTNews ReleaseIntercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
2023-06-23 02:45U:ICPTNews ReleaseIntercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
2023-06-22 17:45U:ICPTNews ReleaseIntercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
2023-06-07 07:00U:ICPTNews ReleaseIntercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023
2023-05-31 08:00U:ICPTNews ReleaseIntercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023
2023-05-19 18:45U:ICPTNews ReleaseIntercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
2023-05-19 07:05U:ICPTNews ReleaseIntercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
2023-05-16 17:00U:ICPTNews ReleaseIntercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)